KEYNOTE-522: Pembrolizumab in Triple-Negative Breast Cancer

Opinion
Video

Erika P. Hamilton, MD, and the Oncology Brothers offer clinical insights on recent data from KEYNOTE-522 on pembrolizumab in patients with triple-negative breast cancer.

Newsletter

Stay up to date on practice-changing data in community practice.

Subscribe Now!
Recent Videos
Related Content
Phase 1b Data Suggest Paxalisib Combo May Suppress CTCs in Metastatic TNBC

Phase 1b Data Suggest Paxalisib Combo May Suppress CTCs in Metastatic TNBC

Jordyn Sava
July 10th 2025
Article

A promising clinical trial shows that a combination of paxalisib, pembrolizumab, and chemotherapy significantly reduces circulating tumor cells in metastatic triple-negative breast cancer.

Read More

Behind the FDA Approval of Dato-DXd in HR+/HER2– Breast Cancer With Bardia

Behind the FDA Approval of Dato-DXd in HR+/HER2– Breast Cancer With Bardia

Jordyn Sava;Aditya Bardia, MD, MPH
February 6th 2025
Podcast

In this episode of Targeted Talks, Aditya Bardia, MD, MPH, FASCO, discusses the recent FDA approval of datopotamab deruxtecan in breast cancer.

Listen

Gedatolisib Shows Encouraging Early Efficacy in mCRPC and HER2+ mBC

Gedatolisib Shows Encouraging Early Efficacy in mCRPC and HER2+ mBC

Sabrina Serani
July 3rd 2025
Article

Preliminary data highlights gedatolisib's potential in treating mCRPC and HER2+ mBC, showcasing promising efficacy and a favorable safety profile.

Read More

Juneja Explores AI’s Impact in Early Cancer Detection and Treatment

Juneja Explores AI’s Impact in Early Cancer Detection and Treatment

Jordyn Sava;Sanjay K. Juneja, MD
January 15th 2025
Podcast

In this episode of Targeted Talks, Sanjay K. Juneja, MD, discusses the exciting advancements of artificial intelligence in 2024.

Listen

TROP-2 Inhibitors Are Explored in Breast Cancer

TROP-2 Inhibitors Are Explored in Breast Cancer

Tony Berberabe, MPH
June 28th 2025
Article

Discover the latest advancements in breast cancer treatment at the 24th Annual International Congress, featuring expert insights and groundbreaking research.

Read More

Yan Emphasizes Use of Supportive Care With Dato-DXd in Breast Cancer

Yan Emphasizes Use of Supportive Care With Dato-DXd in Breast Cancer

Targeted Oncology Staff
June 26th 2025
Article

During a live event, Fengting Yan, MD, PhD, discussed safety outcomes from the TROPION-Breast01 and supportive care for datopotamab deruxtecan in metastatic breast cancer.

Read More